256 related articles for article (PubMed ID: 21615174)
1. Comparative proteomic analysis implicates COMMD proteins as Epstein-Barr virus targets in the BL41 Burkitt's lymphoma cell line.
Gkiafi Z; Panayotou G
J Proteome Res; 2011 Jul; 10(7):2959-68. PubMed ID: 21615174
[TBL] [Abstract][Full Text] [Related]
2. Regulation of interleukin-1beta transcription by Epstein-Barr virus involves a number of latent proteins via their interaction with RBP.
Krauer KG; Belzer DK; Liaskou D; Buck M; Cross S; Honjo T; Sculley T
Virology; 1998 Dec; 252(2):418-30. PubMed ID: 9878621
[TBL] [Abstract][Full Text] [Related]
3. Transactivation of CCL20 gene by Epstein-Barr virus latent membrane protein 1.
Okudaira T; Yamamoto K; Kawakami H; Uchihara JN; Tomita M; Masuda M; Matsuda T; Sairenji T; Iha H; Jeang KT; Matsuyama T; Takasu N; Mori N
Br J Haematol; 2006 Feb; 132(3):293-302. PubMed ID: 16409294
[TBL] [Abstract][Full Text] [Related]
4. H2O2 inhibits BCR-dependent immediate early induction of EBV genes in Burkitt's lymphoma cells.
Osipova-Goldberg HI; Turchanowa LV; Adler B; Pfeilschifter JM
Free Radic Biol Med; 2009 Oct; 47(8):1120-9. PubMed ID: 19540913
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
De Leo A; Arena G; Stecca C; Raciti M; Mattia E
Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
[TBL] [Abstract][Full Text] [Related]
6. Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion.
Ho CH; Chen CL; Li WY; Chen CJ
Carcinogenesis; 2009 Aug; 30(8):1443-51. PubMed ID: 19483191
[TBL] [Abstract][Full Text] [Related]
7. Role of LMP1 in immune control of EBV infection.
Pai S; Khanna R
Semin Cancer Biol; 2001 Dec; 11(6):455-60. PubMed ID: 11669607
[TBL] [Abstract][Full Text] [Related]
8. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.
Giunco S; Dolcetti R; Keppel S; Celeghin A; Indraccolo S; Dal Col J; Mastorci K; De Rossi A
Clin Cancer Res; 2013 Apr; 19(8):2036-47. PubMed ID: 23444223
[TBL] [Abstract][Full Text] [Related]
9. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
[TBL] [Abstract][Full Text] [Related]
10. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
11. Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin.
Hsu CH; Hergenhahn M; Chuang SE; Yeh PY; Wu TC; Gao M; Cheng AL
Anticancer Res; 2002; 22(6C):4065-71. PubMed ID: 12553034
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus latent membrane protein-1 activates CD25 expression in lymphoma cells involving the NFkappaB pathway.
Vockerodt M; Tesch H; Kube D
Genes Immun; 2001 Dec; 2(8):433-41. PubMed ID: 11781710
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways.
D'Addario M; Libermann TA; Xu J; Ahmad A; Menezes J
J Mol Biol; 2001 May; 308(3):501-14. PubMed ID: 11327783
[TBL] [Abstract][Full Text] [Related]
14. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line.
Ren Q; Sato H; Murono S; Furukawa M; Yoshizaki T
Laryngoscope; 2004 May; 114(5):855-9. PubMed ID: 15126743
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus: 40 years on.
Young LS; Rickinson AB
Nat Rev Cancer; 2004 Oct; 4(10):757-68. PubMed ID: 15510157
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus encoded BALF1 gene is transcribed in Burkitt's lymphoma cell lines and in nasopharyngeal carcinoma's biopsies.
Cabras G; Decaussin G; Zeng Y; Djennaoui D; Melouli H; Broully P; Bouguermouh AM; Ooka T
J Clin Virol; 2005 Sep; 34(1):26-34. PubMed ID: 16087121
[TBL] [Abstract][Full Text] [Related]
18. Cell-cycle regulators, bcl-2 and NF-kappaB in Epstein-Barr virus-positive gastric carcinomas.
Chang MS; Lee HS; Jung EJ; Kim CW; Lee BL; Kim WH
Int J Oncol; 2005 Nov; 27(5):1265-72. PubMed ID: 16211221
[TBL] [Abstract][Full Text] [Related]
19. CD44 isoforms containing exons V6 and V7 are differentially expressed on mitogenically stimulated normal and Epstein-Barr virus-transformed human B cells.
Kryworuckho M; Diaz-Mitoma F; Kumar A
Immunology; 1995 Sep; 86(1):41-8. PubMed ID: 7590880
[TBL] [Abstract][Full Text] [Related]
20. Expression of interleukin 10 in B lymphocytes of different origin.
Finke J; Ternes P; Lange W; Mertelsmann R; Dölken G
Leukemia; 1993 Nov; 7(11):1852-7. PubMed ID: 7694007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
